GlobeNewswire Inc | Sep 9, 2021 08:00AM EDT

September 09, 2021

OXFORD, United Kingdom, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that Bill Enright, Chief Executive Officer, will be presenting at the following investment conferences in September.

Event: Morgan Stanley Healthcare Conference 2021Date: Thursday, September 9Presentation: Fireside chatTime: 11:45 a.m. EDTWebcast: Events section of the Vaccitech website Event: H.C. Wainwright 23^rd Annual Global Investment ConferenceDate: Monday, September 13 - Wednesday, September 15Presentation: On demand, virtual presentationPanel: On demand, Best Practices ? Planning for the Next PandemicTime: 7 a.m. EDTWebcast: Requires conference portal log-in

About Vaccitech plcVaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The companys proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Media contacts:Katja Stout, Scius Communications (EU)Direct: +44 (0) 7789435990Email:katja@sciuscommunications.com

Robert Flamm, Ph.D. / Harrison Wong, Burns McClellan, Inc. (US)212-213-0006 ext. 364 / 316Email:rflamm@burnsmc.com / hwong@burnsmc.com

Henry Hodge, Vaccitech (UK)Email:henry.hodge@vaccitech.co.uk